Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Pravastatin
- Accession Number
- DB00175 (APRD00328)
- Type
- Small Molecule
- Groups
- Approved
- Description
Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered. It is a ring-opened dihydroxyacid with a 6’-hydroxyl group that does not require in vivo activation. Pravastatin is one of the lower potency statins; however, its increased hydrophilicity is thought to confer advantages such as minimal penetration through lipophilic membranes of peripheral cells, increased selectivity for hepatic tissues, and a reduction in side effects compared with lovastatin and simvastatin.
- Structure
Structure for DB00175 (Pravastatin)
- Synonyms
- (+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
- Pravastatin acid
- Pravastatina
- Pravastatine
- Pravastatinum
- Product Ingredients
Ingredient UNII CAS InChI Key Pravastatin sodium 3M8608UQ61 81131-70-6 VWBQYTRBTXKKOG-IYNICTALSA-M - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Act Pravastatin Tablet 10 mg Oral Actavis Pharma Company 2003-12-09 Not applicable Canada 
Act Pravastatin Tablet 40 mg Oral Actavis Pharma Company 2003-12-09 Not applicable Canada Act Pravastatin Tablet 20 mg Oral Actavis Pharma Company 2003-12-09 Not applicable Canada Bio Pravastatin Tablet 10 mg Oral Bioenhance Medicines Inc. 2001-07-12 2003-02-27 Canada Bio Pravastatin Tablet 40 mg Oral Bioenhance Medicines Inc. 2001-07-12 2003-02-27 Canada Bio Pravastatin Tablet 20 mg Oral Bioenhance Medicines Inc. 2001-07-12 2003-02-27 Canada M-pravastatin Tablet 20 mg Oral Mantra Pharma Inc Not applicable Not applicable Canada M-pravastatin Tablet 10 mg Oral Mantra Pharma Inc Not applicable Not applicable Canada M-pravastatin Tablet 40 mg Oral Mantra Pharma Inc Not applicable Not applicable Canada Pravachol Tablet 40 mg/1 Oral E.R. Squibb & Sons, L.L.C. 2009-06-01 Not applicable US 
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Ach-pravastatin Tablet 40 mg Oral Accord Healthcare Limited Not applicable Not applicable Canada Ach-pravastatin Tablet 20 mg Oral Accord Healthcare Limited Not applicable Not applicable Canada Ach-pravastatin Tablet 10 mg Oral Accord Healthcare Limited Not applicable Not applicable Canada Apo-pravastatin Tablet 20 mg Oral Apotex Corporation 2001-02-27 Not applicable Canada Apo-pravastatin Tablet 10 mg Oral Apotex Corporation 2001-02-27 Not applicable Canada Apo-pravastatin Tablet 40 mg Oral Apotex Corporation 2001-02-27 Not applicable Canada Auro-pravastatin Tablet 40 mg Oral Auro Pharma Inc Not applicable Not applicable Canada Auro-pravastatin Tablet 20 mg Oral Auro Pharma Inc Not applicable Not applicable Canada Auro-pravastatin Tablet 10 mg Oral Auro Pharma Inc Not applicable Not applicable Canada Ava-pravastatin Tablet 40 mg Oral Avanstra Inc 2011-10-11 2011-12-12 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Pal-pravastatin-asa Pravastatin sodium (10 mg) + Acetylsalicylic acid (81 mg) Kit; Tablet; Tablet, delayed release Oral Paladin Labs Inc 2006-01-13 2015-07-31 Canada Pal-pravastatin-asa Pravastatin sodium (40 mg) + Acetylsalicylic acid (81 mg) Kit; Tablet; Tablet, delayed release Oral Paladin Labs Inc 2006-01-13 2015-07-31 Canada Pal-pravastatin-asa Pravastatin sodium (20 mg) + Acetylsalicylic acid (81 mg) Kit; Tablet; Tablet, delayed release Oral Paladin Labs Inc 2006-01-13 2015-07-31 Canada - International/Other Brands
- Elisor / Lipostat / Mevalotin / Pravaselect / Selipran
- Categories
- Anticholesteremic Agents
- BCRP/ABCG2 Inhibitors
- BCRP/ABCG2 Substrates
- Cardiovascular System
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A5 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Enzyme Inhibitors
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hypolipidemic Agents
- Lipid Modifying Agents
- Lipid Modifying Agents, Plain
- Lipid Regulating Agents
- Naphthalenes
- Noxae
- OAT3 Substrates
- OATP1B1 transporter inhibitors
- OATP1B1/SLCO1B1 Substrates
- P-glycoprotein/ABCB1 Substrates
- Toxic Actions
- UNII
- KXO2KT9N0G
- CAS number
- 81093-37-0
- Weight
- Average: 424.5277
Monoisotopic: 424.246103506 - Chemical Formula
- C23H36O7
- InChI Key
- TUZYXOIXSAXUGO-PZAWKZKUSA-N
- InChI
- InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1
- IUPAC Name
- (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
- SMILES
- [H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC
Pharmacology
- Indication
For the treatment of hypercholesterolemia and to reduce the risk of cardiovascular disease.
- Associated Conditions
- Pharmacodynamics
The primary cause of cardiovascular (CV) disease is atherosclerotic plaque formation and sustained elevation of cholesterol in the blood increases the risk of CV disease. Pravastatin lowers hepatic production of cholesterol by competitively inhibiting HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in the cholesterol biosynthesis pathway via the mevalonic acid pathway. Decreased hepatic cholesterol levels causes increased uptake of low density lipoprotein (LDL) cholesterol and reduces cholesterol levels in the circulation. Pravastatin also inhibits hepatic synthesis if VLDL. At therapeutic doses, pravastatin lowers LDL cholesterol by 20-30%, increase high density lipoprotein (HDL) cholesterol by 3-10%, and decrease plasma triglycerides by 19-34%. HDL cholesterol is thought to confer protective effects against CV disease, whereas high LDL and triglyceride levels are associated with higher risk of disease.
- Mechanism of action
Pravastatin is structurally similar to the HMG, a substituent of the endogenous substrate of HMG-CoA reductase. Unlike its parent compound, mevastatin, and statins such as lovastatin and simvastatin, pravastatin does not need to be activated in vivo. Its hydrolyzed lactone ring mimics the tetrahedral intermediate produced by the reductase allowing the agent to bind with a much greater affinity than its natural substrate. The bicyclic portion of pravastatin binds to the coenzyme A portion of the active site. Pravastatin sodium produces its lipid-lowering effect in two ways. First, as a consequence of its reversible inhibition of HMG-CoA reductase activity, it effects modest reductions in intracellular pools of cholesterol. This results in an increase in the number of LDL-receptors on cell surfaces and enhanced receptor-mediated catabolism and clearance of circulating LDL. Second, pravastatin inhibits LDL production by inhibiting hepatic synthesis of VLDL, the LDL precursor.
Target Actions Organism A3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitorHuman - Absorption
Pravastatin is rapidly absorbed with peak plasma levels of the parent compound achieved 1 to 1.5 hours after administration. The average oral absorption of pravastatin is 34% and absolute bioavailability is 17%. These values however, are variable. Food decreases the systemic bioavailability but the lipid-lowering effect is not impacted. When 20 mg of pravastatin is given orally, the pharmacokinetic parameters are as follows: Cmax = 23.3-26.3 ng/mL; AUC = 54.7 to 62.2 ng•hr/mL.
- Volume of distribution
- Not Available
- Protein binding
50% bound to human plasma proteins.
- Metabolism
Hepatic, there is a small amount of metabolism by P450 enzymes, but this effect is so minimal that inhibitory pharmacokinetic drug interactions have no real effect on its overall activity and elimination. An in vitro study which found moderate affinity for P450 2C9 (major), 2D6 and 3A4. Furthermore, the major degradation product is the 3α-hydroxy isomeric metabolite, which has one-tenth to one-fortieth the HMG-CoA reductase inhibitory activity of the parent compound.
- Route of elimination
Approximately 20% of a radiolabeled oral dose is excreted in urine and 70% in the feces. After intravenous administration, 47% of total body clearance was via renal excretion, while 53% was eliminated by non-renal routes.
- Half life
77 hours
- Clearance
- Not Available
- Toxicity
Side effects include diarrhea, nausea, constipation, gas abdominal pain, myopathy, myositis, rhabdomyolysis, and hepatotoxicity. LD50= 12,000 mg/kg (orally in rat)
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Pravastatin Action Pathway Drug action - Pharmacogenomic Effects/ADRs
Interacting Gene/Enzyme Allele name Genotype(s) Defining Change(s) Type(s) Description Details Kinesin-like protein KIF6 --- (C;C) / (C;T) C Allele Effect Directly Studied Patients with this genotype have a greater reduction in risk of a major cardiovascular event with high dose pravastatin. Details 3-hydroxy-3-methylglutaryl-coenzyme A reductase --- (A;T) T Allele Effect Directly Studied Patients with this genotype have a lesser reduction in LDL cholesterol with pravastatin. Details
Interactions
- Drug Interactions
Drug Interaction Drug group 6-Deoxyerythronolide B The risk or severity of rhabdomyolysis can be increased when 6-Deoxyerythronolide B is combined with Pravastatin. Experimental Abiraterone The metabolism of Pravastatin can be decreased when combined with Abiraterone. Approved Acetaminophen The serum concentration of Pravastatin can be increased when it is combined with Acetaminophen. Approved Acetazolamide The serum concentration of Pravastatin can be increased when it is combined with Acetazolamide. Approved, Vet Approved Acetyl sulfisoxazole The serum concentration of Pravastatin can be increased when it is combined with Acetyl sulfisoxazole. Approved, Vet Approved Acipimox Acipimox may increase the myopathic rhabdomyolysis activities of Pravastatin. Approved, Investigational Afatinib The serum concentration of Afatinib can be increased when it is combined with Pravastatin. Approved Aldesleukin The serum concentration of Pravastatin can be increased when it is combined with Aldesleukin. Approved Almasilate The serum concentration of Pravastatin can be decreased when it is combined with Almasilate. Approved, Experimental Aloglutamol The serum concentration of Pravastatin can be decreased when it is combined with Aloglutamol. Approved Alprazolam The serum concentration of Pravastatin can be increased when it is combined with Alprazolam. Approved, Illicit, Investigational Aluminium The serum concentration of Pravastatin can be decreased when it is combined with Aluminium. Approved, Investigational Aluminium acetoacetate The serum concentration of Pravastatin can be decreased when it is combined with Aluminium acetoacetate. Experimental Aluminium glycinate The serum concentration of Pravastatin can be decreased when it is combined with Aluminium glycinate. Experimental Aluminum hydroxide The serum concentration of Pravastatin can be decreased when it is combined with Aluminum hydroxide. Approved, Investigational Ambroxol The serum concentration of Pravastatin can be increased when it is combined with Ambroxol. Approved, Investigational Amiodarone The serum concentration of Pravastatin can be decreased when it is combined with Amiodarone. Approved, Investigational Amlodipine The serum concentration of Pravastatin can be increased when it is combined with Amlodipine. Approved Amodiaquine The serum concentration of Amodiaquine can be increased when it is combined with Pravastatin. Approved, Investigational Amphotericin B The risk or severity of rhabdomyolysis can be increased when Amphotericin B is combined with Pravastatin. Approved, Investigational Amprenavir The serum concentration of Pravastatin can be increased when it is combined with Amprenavir. Approved, Investigational Anastrozole The serum concentration of Pravastatin can be increased when it is combined with Anastrozole. Approved, Investigational Antipyrine The serum concentration of Pravastatin can be increased when it is combined with Antipyrine. Approved, Investigational Apalutamide The serum concentration of Pravastatin can be decreased when it is combined with Apalutamide. Approved, Investigational Aprepitant The serum concentration of Pravastatin can be increased when it is combined with Aprepitant. Approved, Investigational Arsenic trioxide The serum concentration of Pravastatin can be increased when it is combined with Arsenic trioxide. Approved, Investigational Astemizole The serum concentration of Pravastatin can be increased when it is combined with Astemizole. Approved, Withdrawn Asunaprevir The serum concentration of Pravastatin can be increased when it is combined with Asunaprevir. Approved, Investigational, Withdrawn Atazanavir The risk or severity of rhabdomyolysis can be increased when Atazanavir is combined with Pravastatin. Approved, Investigational Atomoxetine The serum concentration of Pravastatin can be increased when it is combined with Atomoxetine. Approved Atorvastatin The risk or severity of adverse effects can be increased when Pravastatin is combined with Atorvastatin. Approved AVE9633 The risk or severity of rhabdomyolysis can be increased when AVE9633 is combined with Pravastatin. Investigational Azelastine The serum concentration of Pravastatin can be increased when it is combined with Azelastine. Approved Azithromycin The serum concentration of Pravastatin can be increased when it is combined with Azithromycin. Approved Betamethasone The serum concentration of Pravastatin can be increased when it is combined with Betamethasone. Approved, Vet Approved Bezafibrate Bezafibrate may increase the myopathic rhabdomyolysis activities of Pravastatin. Approved, Investigational Bicalutamide The serum concentration of Pravastatin can be increased when it is combined with Bicalutamide. Approved Bifonazole The serum concentration of Pravastatin can be increased when it is combined with Bifonazole. Approved, Investigational Bismuth subcitrate potassium The serum concentration of Pravastatin can be decreased when it is combined with Bismuth Subcitrate. Approved, Investigational Bismuth subnitrate The serum concentration of Pravastatin can be decreased when it is combined with Bismuth subnitrate. Approved Boceprevir The serum concentration of Pravastatin can be increased when it is combined with Boceprevir. Approved, Withdrawn Bortezomib The serum concentration of Pravastatin can be increased when it is combined with Bortezomib. Approved, Investigational Bosentan The metabolism of Pravastatin can be increased when combined with Bosentan. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Pravastatin. Approved Brefeldin A The risk or severity of rhabdomyolysis can be increased when Brefeldin A is combined with Pravastatin. Experimental Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Pravastatin. Approved, Investigational Bromocriptine The serum concentration of Pravastatin can be increased when it is combined with Bromocriptine. Approved, Investigational Bryostatin 1 The risk or severity of rhabdomyolysis can be increased when Bryostatin 1 is combined with Pravastatin. Investigational Buprenorphine The serum concentration of Pravastatin can be increased when it is combined with Buprenorphine. Approved, Illicit, Investigational, Vet Approved Cabergoline The serum concentration of Pravastatin can be increased when it is combined with Cabergoline. Approved Caffeine The serum concentration of Pravastatin can be increased when it is combined with Caffeine. Approved Calcium Carbonate The serum concentration of Pravastatin can be decreased when it is combined with Calcium Carbonate. Approved, Investigational Calcium silicate The serum concentration of Pravastatin can be decreased when it is combined with Calcium silicate. Experimental Candicidin The risk or severity of rhabdomyolysis can be increased when Candicidin is combined with Pravastatin. Withdrawn Capecitabine The metabolism of Pravastatin can be decreased when combined with Capecitabine. Approved, Investigational Capsaicin The serum concentration of Pravastatin can be increased when it is combined with Capsaicin. Approved Carbamazepine The metabolism of Pravastatin can be increased when combined with Carbamazepine. Approved, Investigational Carbomycin The risk or severity of rhabdomyolysis can be increased when Carbomycin is combined with Pravastatin. Vet Approved Caspofungin The serum concentration of Pravastatin can be increased when it is combined with Caspofungin. Approved Ceritinib The serum concentration of Pravastatin can be increased when it is combined with Ceritinib. Approved Cerivastatin The serum concentration of Pravastatin can be increased when it is combined with Cerivastatin. Approved, Withdrawn Cethromycin The risk or severity of rhabdomyolysis can be increased when Cethromycin is combined with Pravastatin. Investigational Chloramphenicol The serum concentration of Pravastatin can be increased when it is combined with Chloramphenicol. Approved, Vet Approved Chlorzoxazone The serum concentration of Pravastatin can be increased when it is combined with Chlorzoxazone. Approved Cholecalciferol The metabolism of Pravastatin can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Cholestyramine Cholestyramine can cause a decrease in the absorption of Pravastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Cilostazol The serum concentration of Pravastatin can be increased when it is combined with Cilostazol. Approved, Investigational Cimetidine The serum concentration of Pravastatin can be increased when it is combined with Cimetidine. Approved, Investigational Cimicifuga racemosa The serum concentration of Pravastatin can be increased when it is combined with Cimicifuga racemosa. Approved, Experimental Ciprofibrate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofibrate is combined with Pravastatin. Approved, Investigational Ciprofloxacin The serum concentration of Pravastatin can be increased when it is combined with Ciprofloxacin. Approved, Investigational Cisapride The serum concentration of Pravastatin can be increased when it is combined with Cisapride. Approved, Investigational, Withdrawn Clarithromycin The serum concentration of Pravastatin can be increased when it is combined with Clarithromycin. Approved Clemastine The serum concentration of Pravastatin can be increased when it is combined with Clemastine. Approved, Investigational Clindamycin The serum concentration of Pravastatin can be increased when it is combined with Clindamycin. Approved, Vet Approved Clofazimine The serum concentration of Pravastatin can be increased when it is combined with Clofazimine. Approved, Investigational Clomifene The serum concentration of Pravastatin can be increased when it is combined with Clomifene. Approved, Investigational Clotiazepam The serum concentration of Pravastatin can be increased when it is combined with Clotiazepam. Approved, Illicit Clotrimazole The serum concentration of Pravastatin can be increased when it is combined with Clotrimazole. Approved, Vet Approved Clozapine The serum concentration of Pravastatin can be increased when it is combined with Clozapine. Approved Cobicistat The serum concentration of Pravastatin can be increased when it is combined with Cobicistat. Approved Cocaine The serum concentration of Pravastatin can be increased when it is combined with Cocaine. Approved, Illicit Colchicine Colchicine may increase the myopathic rhabdomyolysis activities of Pravastatin. Approved Colesevelam Colesevelam can cause a decrease in the absorption of Pravastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Pravastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Coltuximab ravtansine The risk or severity of rhabdomyolysis can be increased when Coltuximab ravtansine is combined with Pravastatin. Investigational Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Pravastatin. Approved, Investigational Cortisone acetate The serum concentration of Pravastatin can be increased when it is combined with Cortisone acetate. Approved, Investigational Crisaborole The metabolism of Pravastatin can be decreased when combined with Crisaborole. Approved, Investigational Crizotinib The serum concentration of Pravastatin can be increased when it is combined with Crizotinib. Approved Curcumin The serum concentration of Pravastatin can be increased when it is combined with Curcumin. Approved, Investigational Cyclophosphamide The serum concentration of Pravastatin can be increased when it is combined with Cyclophosphamide. Approved, Investigational Cyclosporine The serum concentration of Pravastatin can be increased when it is combined with Cyclosporine. Approved, Investigational, Vet Approved Cyproterone acetate The serum concentration of Pravastatin can be increased when it is combined with Cyproterone acetate. Approved, Investigational Dabigatran etexilate The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pravastatin. Approved Dabrafenib The serum concentration of Pravastatin can be decreased when it is combined with Dabrafenib. Approved, Investigational Daclatasvir The serum concentration of Pravastatin can be increased when it is combined with Daclatasvir. Approved, Investigational Dalfopristin The serum concentration of Pravastatin can be increased when it is combined with Dalfopristin. Approved Danazol The risk or severity of myopathy and rhabdomyolysis can be increased when Danazol is combined with Pravastatin. Approved Daptomycin The risk or severity of adverse effects can be increased when Pravastatin is combined with Daptomycin. Approved, Investigational Darunavir The serum concentration of Pravastatin can be increased when it is combined with Darunavir. Approved Dasatinib The serum concentration of Pravastatin can be increased when it is combined with Dasatinib. Approved, Investigational Daunorubicin The serum concentration of Pravastatin can be increased when it is combined with Daunorubicin. Approved Deferasirox The serum concentration of Pravastatin can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The serum concentration of Pravastatin can be increased when it is combined with Delavirdine. Approved Desipramine The serum concentration of Pravastatin can be increased when it is combined with Desipramine. Approved, Investigational Dexamethasone The serum concentration of Pravastatin can be increased when it is combined with Dexamethasone. Approved, Investigational, Vet Approved Dextropropoxyphene The serum concentration of Pravastatin can be increased when it is combined with Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Diazepam The serum concentration of Pravastatin can be increased when it is combined with Diazepam. Approved, Illicit, Investigational, Vet Approved Diethylstilbestrol The serum concentration of Pravastatin can be increased when it is combined with Diethylstilbestrol. Approved, Investigational Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Pravastatin. Approved Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Pravastatin. Approved, Experimental Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Pravastatin. Experimental Dihydroergotamine The serum concentration of Pravastatin can be increased when it is combined with Dihydroergotamine. Approved, Investigational Diltiazem The serum concentration of Pravastatin can be increased when it is combined with Diltiazem. Approved, Investigational Dimethyl sulfoxide The serum concentration of Pravastatin can be increased when it is combined with Dimethyl sulfoxide. Approved, Vet Approved Dirithromycin The risk or severity of rhabdomyolysis can be increased when Dirithromycin is combined with Pravastatin. Approved, Investigational Docetaxel The serum concentration of Pravastatin can be increased when it is combined with Docetaxel. Approved, Investigational Doramectin The risk or severity of rhabdomyolysis can be increased when Doramectin is combined with Pravastatin. Vet Approved Dosulepin The metabolism of Pravastatin can be decreased when combined with Dosulepin. Approved Doxorubicin The serum concentration of Pravastatin can be increased when it is combined with Doxorubicin. Approved, Investigational Doxycycline The serum concentration of Pravastatin can be increased when it is combined with Doxycycline. Approved, Investigational, Vet Approved Dronedarone The serum concentration of Pravastatin can be increased when it is combined with Dronedarone. Approved Econazole The serum concentration of Pravastatin can be increased when it is combined with Econazole. Approved Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Pravastatin. Approved Efavirenz The serum concentration of Pravastatin can be decreased when it is combined with Efavirenz. Approved, Investigational Efonidipine The serum concentration of Pravastatin can be increased when it is combined with Efonidipine. Approved, Investigational Elbasvir The serum concentration of Pravastatin can be increased when it is combined with Elbasvir. Approved Eltrombopag The serum concentration of Pravastatin can be increased when it is combined with Eltrombopag. Approved Enasidenib The serum concentration of Pravastatin can be increased when it is combined with Enasidenib. Approved, Investigational Enzalutamide The serum concentration of Pravastatin can be decreased when it is combined with Enzalutamide. Approved Epinephrine The serum concentration of Pravastatin can be increased when it is combined with Epinephrine. Approved, Vet Approved Epofolate The risk or severity of rhabdomyolysis can be increased when Epofolate is combined with Pravastatin. Investigational Epothilone D The risk or severity of rhabdomyolysis can be increased when Epothilone D is combined with Pravastatin. Experimental, Investigational Eprinomectin The risk or severity of rhabdomyolysis can be increased when Eprinomectin is combined with Pravastatin. Vet Approved Ergonovine The serum concentration of Pravastatin can be increased when it is combined with Ergonovine. Approved Ergotamine The serum concentration of Pravastatin can be increased when it is combined with Ergotamine. Approved Erlotinib The risk or severity of adverse effects can be increased when Erlotinib is combined with Pravastatin. Approved, Investigational Erythromycin The serum concentration of Pravastatin can be increased when it is combined with Erythromycin. Approved, Investigational, Vet Approved Ethanol The serum concentration of Pravastatin can be increased when it is combined with Ethanol. Approved Etoposide The serum concentration of Pravastatin can be increased when it is combined with Etoposide. Approved Etoricoxib The serum concentration of Pravastatin can be increased when it is combined with Etoricoxib. Approved, Investigational Etravirine The serum concentration of Pravastatin can be decreased when it is combined with Etravirine. Approved Everolimus The serum concentration of Everolimus can be increased when it is combined with Pravastatin. Approved Ezetimibe The serum concentration of Pravastatin can be increased when it is combined with Ezetimibe. Approved Felodipine The serum concentration of Pravastatin can be increased when it is combined with Felodipine. Approved, Investigational Fenofibrate The risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Pravastatin. Approved Fentanyl The serum concentration of Pravastatin can be increased when it is combined with Fentanyl. Approved, Illicit, Investigational, Vet Approved Fesoterodine The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pravastatin. Approved Floxuridine The metabolism of Pravastatin can be decreased when combined with Floxuridine. Approved Fluconazole The risk or severity of adverse effects can be increased when Fluconazole is combined with Pravastatin. Approved, Investigational Fluorouracil The metabolism of Pravastatin can be decreased when combined with Fluorouracil. Approved Fluoxetine The serum concentration of Pravastatin can be increased when it is combined with Fluoxetine. Approved, Vet Approved Flurithromycin The risk or severity of rhabdomyolysis can be increased when Flurithromycin is combined with Pravastatin. Experimental Fluticasone propionate The serum concentration of Pravastatin can be increased when it is combined with Fluticasone propionate. Approved Fluvastatin The serum concentration of Pravastatin can be increased when it is combined with Fluvastatin. Approved Fluvoxamine The serum concentration of Pravastatin can be increased when it is combined with Fluvoxamine. Approved, Investigational Fosamprenavir The serum concentration of Pravastatin can be increased when it is combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Pravastatin can be increased when it is combined with Fosaprepitant. Approved Fosnetupitant The serum concentration of Pravastatin can be increased when it is combined with Fosnetupitant. Approved Fosphenytoin The serum concentration of Pravastatin can be decreased when it is combined with Fosphenytoin. Approved, Investigational Fusidic Acid The serum concentration of Pravastatin can be increased when it is combined with Fusidic Acid. Approved, Investigational Gemfibrozil The risk or severity of rhabdomyolysis, myoglobinuria, and elevated creatine kinase (CPK) can be increased when Gemfibrozil is combined with Pravastatin. Approved Glyburide The serum concentration of Pravastatin can be increased when it is combined with Glyburide. Approved Glycerol Phenylbutyrate The serum concentration of Pravastatin can be increased when it is combined with Glycerol Phenylbutyrate. Approved GPI-1485 The risk or severity of rhabdomyolysis can be increased when GPI-1485 is combined with Pravastatin. Investigational Haloperidol The serum concentration of Pravastatin can be increased when it is combined with Haloperidol. Approved Histamine The serum concentration of Pravastatin can be increased when it is combined with Histamine. Approved, Investigational Hydralazine The serum concentration of Pravastatin can be increased when it is combined with Hydralazine. Approved Hydrocortisone The serum concentration of Pravastatin can be increased when it is combined with Hydrocortisone. Approved, Vet Approved Hydrotalcite The serum concentration of Pravastatin can be decreased when it is combined with Hydrotalcite. Approved, Experimental, Investigational Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Pravastatin. Approved Idelalisib The serum concentration of Pravastatin can be increased when it is combined with Idelalisib. Approved Ifosfamide The serum concentration of Pravastatin can be increased when it is combined with Ifosfamide. Approved Iloperidone The serum concentration of Pravastatin can be increased when it is combined with Iloperidone. Approved Imatinib The serum concentration of Pravastatin can be increased when it is combined with Imatinib. Approved Indinavir The serum concentration of Pravastatin can be increased when it is combined with Indinavir. Approved Indisulam The serum concentration of Pravastatin can be increased when it is combined with Indisulam. Investigational Irbesartan The serum concentration of Pravastatin can be increased when it is combined with Irbesartan. Approved, Investigational Irinotecan The serum concentration of Pravastatin can be increased when it is combined with Irinotecan. Approved, Investigational Isavuconazole The serum concentration of Pravastatin can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The serum concentration of Pravastatin can be increased when it is combined with Isavuconazonium. Approved, Investigational Isoniazid The serum concentration of Pravastatin can be increased when it is combined with Isoniazid. Approved, Investigational Isradipine The serum concentration of Pravastatin can be increased when it is combined with Isradipine. Approved, Investigational Itraconazole The serum concentration of Pravastatin can be increased when it is combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Pravastatin can be increased when it is combined with Ivacaftor. Approved Ivermectin The risk or severity of rhabdomyolysis can be increased when Ivermectin is combined with Pravastatin. Approved, Investigational, Vet Approved Ixabepilone The risk or severity of rhabdomyolysis can be increased when Ixabepilone is combined with Pravastatin. Approved, Investigational Josamycin The serum concentration of Pravastatin can be increased when it is combined with Josamycin. Approved, Investigational Ketazolam The serum concentration of Pravastatin can be increased when it is combined with Ketazolam. Approved Ketoconazole The serum concentration of Pravastatin can be increased when it is combined with Ketoconazole. Approved, Investigational Kitasamycin The risk or severity of rhabdomyolysis can be increased when Kitasamycin is combined with Pravastatin. Experimental KOS-1584 The risk or severity of rhabdomyolysis can be increased when KOS-1584 is combined with Pravastatin. Investigational Lansoprazole The serum concentration of Pravastatin can be increased when it is combined with Lansoprazole. Approved, Investigational Lanthanum carbonate The serum concentration of Pravastatin can be decreased when it is combined with Lanthanum carbonate. Approved Lapatinib The serum concentration of Pravastatin can be increased when it is combined with Lapatinib. Approved, Investigational Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Pravastatin. Approved Leflunomide The metabolism of Pravastatin can be decreased when combined with Leflunomide. Approved, Investigational Lercanidipine The serum concentration of Pravastatin can be increased when it is combined with Lercanidipine. Approved, Investigational Levofloxacin The serum concentration of Pravastatin can be increased when it is combined with Levofloxacin. Approved, Investigational Levosalbutamol The serum concentration of Pravastatin can be increased when it is combined with Levosalbutamol. Approved, Investigational Lidocaine The serum concentration of Pravastatin can be increased when it is combined with Lidocaine. Approved, Vet Approved Linagliptin The serum concentration of Pravastatin can be increased when it is combined with Linagliptin. Approved Lipegfilgrastim Pravastatin may increase the myelosuppressive activities of Lipegfilgrastim. Approved, Investigational Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Pravastatin. Approved, Investigational Lobeglitazone The metabolism of Pravastatin can be decreased when combined with Lobeglitazone. Approved, Investigational Lomitapide The serum concentration of Pravastatin can be increased when it is combined with Lomitapide. Approved, Investigational Lomustine The serum concentration of Pravastatin can be increased when it is combined with Lomustine. Approved, Investigational Lopinavir The serum concentration of Pravastatin can be increased when it is combined with Lopinavir. Approved Loratadine The serum concentration of Pravastatin can be increased when it is combined with Loratadine. Approved, Investigational Lorpiprazole The serum concentration of Pravastatin can be increased when it is combined with Lorpiprazole. Approved Lorvotuzumab mertansine The risk or severity of rhabdomyolysis can be increased when Lorvotuzumab mertansine is combined with Pravastatin. Investigational Losartan The serum concentration of Pravastatin can be increased when it is combined with Losartan. Approved Lovastatin The serum concentration of Pravastatin can be increased when it is combined with Lovastatin. Approved, Investigational Luliconazole The serum concentration of Pravastatin can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Pravastatin can be decreased when it is combined with Lumacaftor. Approved Lurasidone The serum concentration of Pravastatin can be increased when it is combined with Lurasidone. Approved, Investigational Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Pravastatin. Illicit, Investigational, Withdrawn Magaldrate The serum concentration of Pravastatin can be decreased when it is combined with Magaldrate. Approved, Withdrawn Magnesium carbonate The serum concentration of Pravastatin can be decreased when it is combined with Magnesium carbonate. Approved, Investigational Magnesium hydroxide The serum concentration of Pravastatin can be decreased when it is combined with Magnesium hydroxide. Approved, Investigational Magnesium oxide The serum concentration of Pravastatin can be decreased when it is combined with Magnesium oxide. Approved Magnesium peroxide The serum concentration of Pravastatin can be decreased when it is combined with Magnesium peroxide. Experimental Magnesium silicate The serum concentration of Pravastatin can be decreased when it is combined with Magnesium silicate. Approved Magnesium Trisilicate The serum concentration of Pravastatin can be decreased when it is combined with Magnesium Trisilicate. Approved Manidipine The serum concentration of Pravastatin can be increased when it is combined with Manidipine. Approved, Investigational Mefloquine The serum concentration of Pravastatin can be increased when it is combined with Mefloquine. Approved, Investigational Mepartricin The risk or severity of rhabdomyolysis can be increased when Mepartricin is combined with Pravastatin. Experimental Mequitazine The serum concentration of Pravastatin can be increased when it is combined with Mequitazine. Approved Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Pravastatin. Experimental Methadone The serum concentration of Pravastatin can be increased when it is combined with Methadone. Approved Methazolamide The serum concentration of Pravastatin can be increased when it is combined with Methazolamide. Approved Methimazole The serum concentration of Pravastatin can be increased when it is combined with Methimazole. Approved Methylergometrine The serum concentration of Pravastatin can be increased when it is combined with Methylergometrine. Approved Methylprednisolone The serum concentration of Pravastatin can be increased when it is combined with Methylprednisolone. Approved, Vet Approved Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Pravastatin. Approved Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Pravastatin. Approved, Investigational Metronidazole The serum concentration of Pravastatin can be increased when it is combined with Metronidazole. Approved Metyrapone The serum concentration of Pravastatin can be increased when it is combined with Metyrapone. Approved, Investigational Mevastatin The serum concentration of Mevastatin can be increased when it is combined with Pravastatin. Experimental Mibefradil The serum concentration of Pravastatin can be increased when it is combined with Mibefradil. Investigational, Withdrawn Miconazole The serum concentration of Pravastatin can be increased when it is combined with Miconazole. Approved, Investigational, Vet Approved Midazolam The serum concentration of Pravastatin can be increased when it is combined with Midazolam. Approved, Illicit Midecamycin The risk or severity of rhabdomyolysis can be increased when Midecamycin is combined with Pravastatin. Approved Midostaurin The metabolism of Pravastatin can be decreased when combined with Midostaurin. Approved, Investigational Mifepristone The serum concentration of Pravastatin can be increased when it is combined with Mifepristone. Approved, Investigational Miocamycin The risk or severity of rhabdomyolysis can be increased when Miocamycin is combined with Pravastatin. Experimental Mirtazapine The serum concentration of Pravastatin can be increased when it is combined with Mirtazapine. Approved Mirvetuximab Soravtansine The risk or severity of rhabdomyolysis can be increased when Mirvetuximab Soravtansine is combined with Pravastatin. Investigational Mitemcinal The risk or severity of rhabdomyolysis can be increased when Mitemcinal is combined with Pravastatin. Investigational Mitotane The serum concentration of Pravastatin can be decreased when it is combined with Mitotane. Approved Mitoxantrone The serum concentration of Pravastatin can be increased when it is combined with Mitoxantrone. Approved, Investigational Modafinil The serum concentration of Pravastatin can be increased when it is combined with Modafinil. Approved, Investigational Nabilone The serum concentration of Pravastatin can be increased when it is combined with Nabilone. Approved, Investigational Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Pravastatin. Approved Natamycin The risk or severity of rhabdomyolysis can be increased when Natamycin is combined with Pravastatin. Approved Nefazodone The serum concentration of Pravastatin can be increased when it is combined with Nefazodone. Approved, Withdrawn Nelfinavir The serum concentration of Pravastatin can be decreased when it is combined with Nelfinavir. Approved Netupitant The serum concentration of Pravastatin can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The serum concentration of Pravastatin can be increased when it is combined with Nevirapine. Approved Niacin The risk or severity of rhabdomyolysis can be increased when Niacin is combined with Pravastatin. Approved, Investigational, Nutraceutical Nicardipine The serum concentration of Pravastatin can be increased when it is combined with Nicardipine. Approved, Investigational Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Pravastatin. Approved, Investigational Nicotinamide The serum concentration of Pravastatin can be increased when it is combined with Nicotinamide. Approved, Investigational Nifedipine The serum concentration of Pravastatin can be increased when it is combined with Nifedipine. Approved Nilotinib The serum concentration of Pravastatin can be increased when it is combined with Nilotinib. Approved, Investigational Nilvadipine The serum concentration of Pravastatin can be increased when it is combined with Nilvadipine. Approved, Investigational Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Pravastatin. Approved Nisoldipine The serum concentration of Pravastatin can be increased when it is combined with Nisoldipine. Approved Nitrendipine The serum concentration of Pravastatin can be increased when it is combined with Nitrendipine. Approved, Investigational Nitric Oxide The serum concentration of Pravastatin can be increased when it is combined with Nitric Oxide. Approved Norfloxacin The serum concentration of Pravastatin can be increased when it is combined with Norfloxacin. Approved Noscapine The serum concentration of Pravastatin can be increased when it is combined with Noscapine. Investigational Nystatin The risk or severity of rhabdomyolysis can be increased when Nystatin is combined with Pravastatin. Approved, Vet Approved Olanzapine The serum concentration of Pravastatin can be increased when it is combined with Olanzapine. Approved, Investigational Olaparib The serum concentration of Pravastatin can be increased when it is combined with Olaparib. Approved Oleandomycin The risk or severity of rhabdomyolysis can be increased when Oleandomycin is combined with Pravastatin. Vet Approved Omeprazole The serum concentration of Pravastatin can be increased when it is combined with Omeprazole. Approved, Investigational, Vet Approved Osimertinib The serum concentration of Pravastatin can be increased when it is combined with Osimertinib. Approved Oxetacaine The serum concentration of Pravastatin can be increased when it is combined with Oxetacaine. Approved, Investigational Oxybutynin The serum concentration of Pravastatin can be increased when it is combined with Oxybutynin. Approved, Investigational Oxymetholone The serum concentration of Pravastatin can be increased when it is combined with Oxymetholone. Approved, Illicit Paclitaxel The serum concentration of Pravastatin can be increased when it is combined with Paclitaxel. Approved, Vet Approved Palbociclib The serum concentration of Pravastatin can be increased when it is combined with Palbociclib. Approved, Investigational Paramethasone The serum concentration of Pravastatin can be increased when it is combined with Paramethasone. Approved Paroxetine The risk or severity of increased glucose can be increased when Pravastatin is combined with Paroxetine. Approved, Investigational Patupilone The risk or severity of rhabdomyolysis can be increased when Patupilone is combined with Pravastatin. Experimental, Investigational Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Pravastatin. Approved Pentobarbital The metabolism of Pravastatin can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Peppermint oil The serum concentration of Pravastatin can be increased when it is combined with Peppermint oil. Approved, Investigational Pergolide The serum concentration of Pravastatin can be increased when it is combined with Pergolide. Approved, Investigational, Vet Approved, Withdrawn Phenelzine The serum concentration of Pravastatin can be increased when it is combined with Phenelzine. Approved Phenobarbital The metabolism of Pravastatin can be increased when combined with Phenobarbital. Approved, Investigational Phenytoin The serum concentration of Pravastatin can be decreased when it is combined with Phenytoin. Approved, Vet Approved Pilocarpine The serum concentration of Pravastatin can be increased when it is combined with Pilocarpine. Approved, Investigational Pimecrolimus The risk or severity of rhabdomyolysis can be increased when Pimecrolimus is combined with Pravastatin. Approved, Investigational Pimozide The serum concentration of Pravastatin can be increased when it is combined with Pimozide. Approved Piperaquine The serum concentration of Pravastatin can be increased when it is combined with Piperaquine. Approved, Investigational Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Pravastatin. Approved Pitolisant The serum concentration of Pitolisant can be increased when it is combined with Pravastatin. Approved, Investigational Posaconazole The serum concentration of Pravastatin can be increased when it is combined with Posaconazole. Approved, Investigational, Vet Approved Prednisolone The serum concentration of Pravastatin can be increased when it is combined with Prednisolone. Approved, Vet Approved Prednisone The serum concentration of Pravastatin can be increased when it is combined with Prednisone. Approved, Vet Approved Primaquine The serum concentration of Pravastatin can be increased when it is combined with Primaquine. Approved Primidone The metabolism of Pravastatin can be increased when combined with Primidone. Approved, Vet Approved Progesterone The serum concentration of Pravastatin can be increased when it is combined with Progesterone. Approved, Vet Approved Propofol The serum concentration of Pravastatin can be increased when it is combined with Propofol. Approved, Investigational, Vet Approved Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Pravastatin. Approved Pyrimethamine The metabolism of Pravastatin can be decreased when combined with Pyrimethamine. Approved, Investigational, Vet Approved Quinidine The serum concentration of Pravastatin can be increased when it is combined with Quinidine. Approved, Investigational Quinine The serum concentration of Pravastatin can be increased when it is combined with Quinine. Approved Quinupristin The serum concentration of Pravastatin can be increased when it is combined with Quinupristin. Approved Rabeprazole The serum concentration of Pravastatin can be increased when it is combined with Rabeprazole. Approved, Investigational Raloxifene The serum concentration of Pravastatin can be increased when it is combined with Raloxifene. Approved, Investigational Raltegravir Raltegravir may increase the myopathic rhabdomyolysis activities of Pravastatin. Approved Ranitidine The serum concentration of Pravastatin can be increased when it is combined with Ranitidine. Approved Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Pravastatin. Approved, Investigational Regorafenib The serum concentration of Pravastatin can be increased when it is combined with Regorafenib. Approved Repaglinide The serum concentration of Pravastatin can be increased when it is combined with Repaglinide. Approved, Investigational Resveratrol The serum concentration of Pravastatin can be increased when it is combined with Resveratrol. Approved, Experimental, Investigational Ridaforolimus The risk or severity of rhabdomyolysis can be increased when Ridaforolimus is combined with Pravastatin. Investigational Rifabutin The metabolism of Pravastatin can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The metabolism of Pravastatin can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Pravastatin can be increased when combined with Rifapentine. Approved, Investigational Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Pravastatin. Approved, Investigational Rilpivirine The serum concentration of Rilpivirine can be increased when it is combined with Pravastatin. Approved Risperidone The serum concentration of Pravastatin can be increased when it is combined with Risperidone. Approved, Investigational Ritonavir The serum concentration of Pravastatin can be increased when it is combined with Ritonavir. Approved, Investigational Rivastigmine The serum concentration of Pravastatin can be increased when it is combined with Rivastigmine. Approved, Investigational Rokitamycin The risk or severity of rhabdomyolysis can be increased when Rokitamycin is combined with Pravastatin. Experimental Rolapitant The serum concentration of Pravastatin can be increased when it is combined with Rolapitant. Approved, Investigational Rolitetracycline The serum concentration of Pravastatin can be increased when it is combined with Rolitetracycline. Approved Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Pravastatin. Approved Roxithromycin The serum concentration of Pravastatin can be increased when it is combined with Roxithromycin. Approved, Investigational, Withdrawn Rucaparib The serum concentration of Pravastatin can be increased when it is combined with Rucaparib. Approved, Investigational Rutin The serum concentration of Pravastatin can be increased when it is combined with Rutin. Experimental, Investigational Sagopilone The risk or severity of rhabdomyolysis can be increased when Sagopilone is combined with Pravastatin. Investigational Salbutamol The serum concentration of Pravastatin can be increased when it is combined with Salbutamol. Approved, Vet Approved Saquinavir The serum concentration of Pravastatin can be decreased when it is combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Pravastatin can be decreased when used in combination with Sarilumab. Approved, Investigational Secobarbital The metabolism of Pravastatin can be increased when combined with Secobarbital. Approved, Vet Approved Selamectin The risk or severity of rhabdomyolysis can be increased when Selamectin is combined with Pravastatin. Vet Approved Sertraline The serum concentration of Pravastatin can be increased when it is combined with Sertraline. Approved Sildenafil The serum concentration of Pravastatin can be increased when it is combined with Sildenafil. Approved, Investigational Silodosin The serum concentration of Silodosin can be increased when it is combined with Pravastatin. Approved Siltuximab The serum concentration of Pravastatin can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Pravastatin can be increased when it is combined with Simeprevir. Approved Simvastatin The serum concentration of Pravastatin can be increased when it is combined with Simvastatin. Approved Sirolimus The serum concentration of Pravastatin can be increased when it is combined with Sirolimus. Approved, Investigational Sitaxentan The serum concentration of Pravastatin can be increased when it is combined with Sitaxentan. Approved, Investigational, Withdrawn Sodium bicarbonate The serum concentration of Pravastatin can be decreased when it is combined with Sodium bicarbonate. Approved Sorafenib The serum concentration of Pravastatin can be increased when it is combined with Sorafenib. Approved, Investigational Spiramycin The risk or severity of rhabdomyolysis can be increased when Spiramycin is combined with Pravastatin. Approved St. John's Wort The metabolism of Pravastatin can be increased when combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Pravastatin can be increased when it is combined with Stiripentol. Approved Sulfadiazine The metabolism of Pravastatin can be decreased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Sulfamethoxazole The serum concentration of Pravastatin can be increased when it is combined with Sulfamethoxazole. Approved Sulfanilamide The serum concentration of Pravastatin can be increased when it is combined with Sulfanilamide. Approved Sulfinpyrazone The serum concentration of Pravastatin can be increased when it is combined with Sulfinpyrazone. Approved Sulfisoxazole The serum concentration of Pravastatin can be increased when it is combined with Sulfisoxazole. Approved, Vet Approved Tacrolimus The serum concentration of Pravastatin can be increased when it is combined with Tacrolimus. Approved, Investigational Tadalafil The serum concentration of Pravastatin can be increased when it is combined with Tadalafil. Approved, Investigational Tamoxifen The serum concentration of Pravastatin can be increased when it is combined with Tamoxifen. Approved Telaprevir The serum concentration of Pravastatin can be increased when it is combined with Telaprevir. Approved, Withdrawn Telithromycin The serum concentration of Pravastatin can be increased when it is combined with Telithromycin. Approved Temsirolimus The serum concentration of Pravastatin can be increased when it is combined with Temsirolimus. Approved Teniposide The serum concentration of Pravastatin can be increased when it is combined with Teniposide. Approved Terfenadine The serum concentration of Pravastatin can be increased when it is combined with Terfenadine. Approved, Withdrawn Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Pravastatin. Experimental Teriflunomide The serum concentration of Pravastatin can be increased when it is combined with Teriflunomide. Approved Tesmilifene The serum concentration of Pravastatin can be increased when it is combined with Tesmilifene. Investigational Testosterone The serum concentration of Pravastatin can be increased when it is combined with Testosterone. Approved, Investigational Testosterone cypionate The serum concentration of Pravastatin can be increased when it is combined with Testosterone cypionate. Approved Testosterone enanthate The serum concentration of Pravastatin can be increased when it is combined with Testosterone enanthate. Approved Testosterone undecanoate The serum concentration of Pravastatin can be increased when it is combined with Testosterone undecanoate. Approved, Investigational Tetracycline The serum concentration of Pravastatin can be increased when it is combined with Tetracycline. Approved, Vet Approved Thiopental The serum concentration of Pravastatin can be increased when it is combined with Thiopental. Approved, Vet Approved Thioridazine The serum concentration of Thioridazine can be increased when it is combined with Pravastatin. Approved, Withdrawn Ticagrelor The serum concentration of Pravastatin can be increased when it is combined with Ticagrelor. Approved Ticlopidine The serum concentration of Pravastatin can be increased when it is combined with Ticlopidine. Approved Tildipirosin The risk or severity of rhabdomyolysis can be increased when Tildipirosin is combined with Pravastatin. Vet Approved Tilmicosin The risk or severity of rhabdomyolysis can be increased when Tilmicosin is combined with Pravastatin. Investigational, Vet Approved Tioconazole The serum concentration of Pravastatin can be increased when it is combined with Tioconazole. Approved Tipranavir The serum concentration of Pravastatin can be increased when it is combined with Tipranavir. Approved, Investigational Tocilizumab The serum concentration of Pravastatin can be decreased when it is combined with Tocilizumab. Approved Tofisopam The serum concentration of Pravastatin can be increased when it is combined with Tofisopam. Approved Tolbutamide The metabolism of Pravastatin can be decreased when combined with Tolbutamide. Approved, Investigational Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Pravastatin. Approved Topiroxostat The serum concentration of Pravastatin can be increased when it is combined with Topiroxostat. Approved, Investigational Topotecan The serum concentration of Topotecan can be increased when it is combined with Pravastatin. Approved, Investigational Trabectedin Pravastatin may increase the myopathic rhabdomyolysis activities of Trabectedin. Approved, Investigational Tramadol The serum concentration of Pravastatin can be increased when it is combined with Tramadol. Approved, Investigational Tranylcypromine The serum concentration of Pravastatin can be increased when it is combined with Tranylcypromine. Approved, Investigational Trastuzumab emtansine The risk or severity of rhabdomyolysis can be increased when Trastuzumab emtansine is combined with Pravastatin. Approved, Investigational Trimethoprim The metabolism of Pravastatin can be decreased when combined with Trimethoprim. Approved, Vet Approved Troglitazone The serum concentration of Pravastatin can be increased when it is combined with Troglitazone. Investigational, Withdrawn Troleandomycin The serum concentration of Pravastatin can be increased when it is combined with Troleandomycin. Approved Tromethamine The serum concentration of Pravastatin can be decreased when it is combined with Tromethamine. Approved Tylosin The risk or severity of rhabdomyolysis can be increased when Tylosin is combined with Pravastatin. Vet Approved Tylvalosin The risk or severity of rhabdomyolysis can be increased when Tylvalosin is combined with Pravastatin. Vet Approved Ubidecarenone The serum concentration of Ubidecarenone can be decreased when it is combined with Pravastatin. Approved, Investigational, Nutraceutical Valproic Acid The serum concentration of Pravastatin can be increased when it is combined with Valproic Acid. Approved, Investigational Valsartan The metabolism of Pravastatin can be decreased when combined with Valsartan. Approved, Investigational Vemurafenib The serum concentration of Pravastatin can be increased when it is combined with Vemurafenib. Approved Venlafaxine The serum concentration of Pravastatin can be increased when it is combined with Venlafaxine. Approved Verapamil The serum concentration of Pravastatin can be increased when it is combined with Verapamil. Approved Vinblastine The serum concentration of Pravastatin can be increased when it is combined with Vinblastine. Approved Vincristine The serum concentration of Pravastatin can be increased when it is combined with Vincristine. Approved, Investigational Vincristine The excretion of Vincristine can be decreased when combined with Pravastatin. Approved, Investigational Vinorelbine The serum concentration of Pravastatin can be increased when it is combined with Vinorelbine. Approved, Investigational Voriconazole The serum concentration of Pravastatin can be increased when it is combined with Voriconazole. Approved, Investigational Zafirlukast The serum concentration of Pravastatin can be increased when it is combined with Zafirlukast. Approved, Investigational Ziprasidone The serum concentration of Pravastatin can be increased when it is combined with Ziprasidone. Approved Zucapsaicin The serum concentration of Pravastatin can be increased when it is combined with Zucapsaicin. Approved, Investigational - Food Interactions
- Avoid alcohol.
- Avoid drastic changes in dietary habit.
- Take without regard to meals.
References
- Synthesis Reference
Kae Jong Chung, Joo Kyung Lee, Joo Woong Park, Dong Jin Seo, Sang Choon Lee, "Method for producing pravastatin precursor, ML-236B." U.S. Patent US6204032, issued October, 1976.
US6204032- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0005022
- KEGG Drug
- D08410
- KEGG Compound
- C01844
- PubChem Compound
- 54687
- PubChem Substance
- 46504851
- ChemSpider
- 49398
- BindingDB
- 20688
- ChEBI
- 63618
- ChEMBL
- CHEMBL1144
- Therapeutic Targets Database
- DAP000550
- PharmGKB
- PA451089
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Pravastatin
- ATC Codes
- C10AA03 — Pravastatin
- C10AA — HMG CoA reductase inhibitors
- C10A — LIPID MODIFYING AGENTS, PLAIN
- C10 — LIPID MODIFYING AGENTS
- C — CARDIOVASCULAR SYSTEM
- C10BX — HMG CoA reductase inhibitors, other combinations
- C10B — LIPID MODIFYING AGENTS, COMBINATIONS
- C10 — LIPID MODIFYING AGENTS
- C — CARDIOVASCULAR SYSTEM
- AHFS Codes
- 24:06.08 — Hmg-coa Reductase Inhibitors
- FDA label
- Download (145 KB)
- MSDS
- Download (44 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Bristol myers squibb
- Apotex corp
- Dr reddys laboratories inc
- Glenmark generics ltd
- Lek pharmaceuticals dd
- Lupin pharmaceuticals inc
- Matrix laboratories ltd
- Mylan pharmaceuticals inc
- Pliva hrvatska doo
- Ranbaxy laboratories ltd
- Teva pharmaceuticals usa inc
- Teva pharmaceuticals usa
- Watson laboratories inc
- Zydus pharmaceuticals usa inc
- Packagers
- Advanced Pharmaceutical Services Inc.
- Amerisource Health Services Corp.
- Apotex Inc.
- A-S Medication Solutions LLC
- Bristol-Myers Squibb Co.
- Bryant Ranch Prepack
- Cadila Healthcare Ltd.
- Cardinal Health
- Cobalt Pharmaceuticals Inc.
- Comprehensive Consultant Services Inc.
- Dept Health Central Pharmacy
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Doctor Reddys Laboratories Ltd.
- E.R. Squibb and Sons LLC
- Glenmark Generics Ltd.
- International Laboratories Inc.
- Kaiser Foundation Hospital
- Lek Pharmaceuticals Inc.
- Lupin Pharmaceuticals Inc.
- Major Pharmaceuticals
- Medvantx Inc.
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Neuman Distributors Inc.
- Ohm Laboratories Inc.
- Palmetto Pharmaceuticals Inc.
- Par Pharmaceuticals
- PD-Rx Pharmaceuticals Inc.
- Pharmaceutical Utilization Management Program VA Inc.
- Physicians Total Care Inc.
- Pliva Inc.
- Prepackage Specialists
- Prepak Systems Inc.
- Ranbaxy Laboratories
- Rebel Distributors Corp.
- Resource Optimization and Innovation LLC
- Sandoz
- Southwood Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- UDL Laboratories
- Vangard Labs Inc.
- Zydus Pharmaceuticals
- Dosage forms
Form Route Strength Tablet Oral 10 mg Kit; tablet; tablet, delayed release Oral Tablet Oral 80 mg Tablet Oral 20 mg Tablet Oral 40 mg Tablet Oral 10 mg/1 Tablet Oral 20 mg/1 Tablet Oral 40 mg/1 Tablet Oral 80 mg/1 - Prices
Unit description Cost Unit Pravachol 40 mg tablet 6.53USD tablet Pravachol 80 mg tablet 6.53USD tablet Pravastatin sodium 40 mg tablet 4.89USD tablet Pravastatin sodium 80 mg tablet 4.89USD tablet Pravachol 20 mg tablet 4.39USD tablet Pravachol 10 mg tablet 4.38USD tablet Pravastatin sodium 20 mg tablet 3.33USD tablet Pravastatin sodium 10 mg tablet 3.28USD tablet Apo-Pravastatin 40 mg Tablet 1.42USD tablet Co Pravastatin 40 mg Tablet 1.42USD tablet Jamp-Pravastatin 40 mg Tablet 1.42USD tablet Mint-Pravastatin 40 mg Tablet 1.42USD tablet Mylan-Pravastatin 40 mg Tablet 1.42USD tablet Novo-Pravastatin 40 mg Tablet 1.42USD tablet Pms-Pravastatin 40 mg Tablet 1.42USD tablet Pravachol 40 mg Tablet 1.42USD tablet Ran-Pravastatin 40 mg Tablet 1.42USD tablet Ratio-Pravastatin 40 mg Tablet 1.42USD tablet Sandoz Pravastatin 40 mg Tablet 1.42USD tablet Apo-Pravastatin 20 mg Tablet 1.18USD tablet Co Pravastatin 20 mg Tablet 1.18USD tablet Jamp-Pravastatin 20 mg Tablet 1.18USD tablet Mint-Pravastatin 20 mg Tablet 1.18USD tablet Mylan-Pravastatin 20 mg Tablet 1.18USD tablet Novo-Pravastatin 20 mg Tablet 1.18USD tablet Pms-Pravastatin 20 mg Tablet 1.18USD tablet Pravachol 20 mg Tablet 1.18USD tablet Ran-Pravastatin 20 mg Tablet 1.18USD tablet Ratio-Pravastatin 20 mg Tablet 1.18USD tablet Sandoz Pravastatin 20 mg Tablet 1.18USD tablet Apo-Pravastatin 10 mg Tablet 1.0USD tablet Co Pravastatin 10 mg Tablet 1.0USD tablet Jamp-Pravastatin 10 mg Tablet 1.0USD tablet Mint-Pravastatin 10 mg Tablet 1.0USD tablet Mylan-Pravastatin 10 mg Tablet 1.0USD tablet Novo-Pravastatin 10 mg Tablet 1.0USD tablet Pms-Pravastatin 10 mg Tablet 1.0USD tablet Pravachol 10 mg Tablet 1.0USD tablet Ran-Pravastatin 10 mg Tablet 1.0USD tablet Ratio-Pravastatin 10 mg Tablet 1.0USD tablet Sandoz Pravastatin 10 mg Tablet 1.0USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5622985 No 1994-10-22 2014-10-22 US CA1323836 No 1993-11-02 2010-11-02 Canada
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 171.2 - 173°C MSDS water solubility Soluble FDA label logP 0.59 FDA label - Predicted Properties
Property Value Source Water Solubility 0.242 mg/mL ALOGPS logP 2.23 ALOGPS logP 1.65 ChemAxon logS -3.2 ALOGPS pKa (Strongest Acidic) 4.21 ChemAxon pKa (Strongest Basic) -2.7 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 124.29 Å2 ChemAxon Rotatable Bond Count 11 ChemAxon Refractivity 113.6 m3·mol-1 ChemAxon Polarizability 46.56 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as medium-chain hydroxy acids and derivatives. These are hydroxy acids with a 6 to 12 carbon atoms long side chain.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Hydroxy acids and derivatives
- Sub Class
- Medium-chain hydroxy acids and derivatives
- Direct Parent
- Medium-chain hydroxy acids and derivatives
- Alternative Parents
- Fatty alcohols / Medium-chain fatty acids / Hydroxy fatty acids / Fatty acid esters / Branched fatty acids / Beta hydroxy acids and derivatives / Dicarboxylic acids and derivatives / Secondary alcohols / Carboxylic acid esters / Carboxylic acids show 3 more
- Substituents
- Fatty alcohol / Medium-chain hydroxy acid / Medium-chain fatty acid / Beta-hydroxy acid / Branched fatty acid / Hydroxy fatty acid / Fatty acid ester / Fatty acyl / Dicarboxylic acid or derivatives / Secondary alcohol show 10 more
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- statin (semi-synthetic), carboxylic ester, secondary alcohol, 3-hydroxy carboxylic acid, hydroxy monocarboxylic acid, carbobicyclic compound (CHEBI:63618)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Nadph binding
- Specific Function
- Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including...
- Gene Name
- HMGCR
- Uniprot ID
- P04035
- Uniprot Name
- 3-hydroxy-3-methylglutaryl-coenzyme A reductase
- Molecular Weight
- 97475.155 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C8
- Uniprot ID
- P10632
- Uniprot Name
- Cytochrome P450 2C8
- Molecular Weight
- 55824.275 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
- Gene Name
- SLCO1B1
- Uniprot ID
- Q9Y6L6
- Uniprot Name
- Solute carrier organic anion transporter family member 1B1
- Molecular Weight
- 76447.99 Da
References
- Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150]
- Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278]
- Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
- Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22. [PubMed:15970799]
- Sharma P, Holmes VE, Elsby R, Lambert C, Surry D: Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. Xenobiotica. 2010 Jan;40(1):24-37. doi: 10.3109/00498250903351013. [PubMed:19919292]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
- Gene Name
- SLCO2B1
- Uniprot ID
- O94956
- Uniprot Name
- Solute carrier organic anion transporter family member 2B1
- Molecular Weight
- 76709.98 Da
References
- Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ: Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009 Feb;19(2):129-38. doi: 10.1097/FPC.0b013e32831bd98c. [PubMed:19151602]
- Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003 Aug;306(2):703-8. Epub 2003 Apr 30. [PubMed:12724351]
- Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45. Epub 2003 Nov 10. [PubMed:14610227]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150]
- Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
- Gene Name
- SLCO1A2
- Uniprot ID
- P46721
- Uniprot Name
- Solute carrier organic anion transporter family member 1A2
- Molecular Weight
- 74144.105 Da
References
- Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
- Gene Name
- SLC22A6
- Uniprot ID
- Q4U2R8
- Uniprot Name
- Solute carrier family 22 member 6
- Molecular Weight
- 61815.78 Da
References
- Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
- Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, Sugiyama Y: Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther. 2002 Mar;300(3):746-53. [PubMed:11861777]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
- Gene Name
- SLC22A8
- Uniprot ID
- Q8TCC7
- Uniprot Name
- Solute carrier family 22 member 8
- Molecular Weight
- 59855.585 Da
References
- Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
- Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099]
- Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, Sugiyama Y: Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther. 2002 Mar;300(3):746-53. [PubMed:11861777]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Organic anion transmembrane transporter activity
- Specific Function
- Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
- Gene Name
- ABCC2
- Uniprot ID
- Q92887
- Uniprot Name
- Canalicular multispecific organic anion transporter 1
- Molecular Weight
- 174205.64 Da
References
- Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150]
- Yamazaki M, Akiyama S, Ni'inuma K, Nishigaki R, Sugiyama Y: Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos. 1997 Oct;25(10):1123-9. [PubMed:9321514]
- Sasaki M, Suzuki H, Ito K, Abe T, Sugiyama Y: Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J Biol Chem. 2002 Feb 22;277(8):6497-503. Epub 2001 Dec 17. [PubMed:11748225]
- Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
- Gene Name
- SLC22A11
- Uniprot ID
- Q9NSA0
- Uniprot Name
- Solute carrier family 22 member 11
- Molecular Weight
- 59970.945 Da
References
- Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
- Gene Name
- ABCG2
- Uniprot ID
- Q9UNQ0
- Uniprot Name
- ATP-binding cassette sub-family G member 2
- Molecular Weight
- 72313.47 Da
References
- Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9. Epub 2003 Apr 7. [PubMed:12682043]
- Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
- Gene Name
- SLC22A7
- Uniprot ID
- Q9Y694
- Uniprot Name
- Solute carrier family 22 member 7
- Molecular Weight
- 60025.025 Da
References
- Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Symporter activity
- Specific Function
- Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucin...
- Gene Name
- SLC16A1
- Uniprot ID
- P53985
- Uniprot Name
- Monocarboxylate transporter 1
- Molecular Weight
- 53943.685 Da
References
- Tamai I, Takanaga H, Maeda H, Ogihara T, Yoneda M, Tsuji A: Proton-cotransport of pravastatin across intestinal brush-border membrane. Pharm Res. 1995 Nov;12(11):1727-32. [PubMed:8592677]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Transporter activity
- Specific Function
- Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
- Gene Name
- ABCB11
- Uniprot ID
- O95342
- Uniprot Name
- Bile salt export pump
- Molecular Weight
- 146405.83 Da
References
- Morisawa Y, Takikawa H: Effect of bile acids on the biliary excretion of pravastatin in rats. Hepatol Res. 2009 Jun;39(6):595-600. doi: 10.1111/j.1872-034X.2009.00493.x. Epub 2009 Feb 24. [PubMed:19260999]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
- Gene Name
- SLCO1B3
- Uniprot ID
- Q9NPD5
- Uniprot Name
- Solute carrier organic anion transporter family member 1B3
- Molecular Weight
- 77402.175 Da
References
- Link [Link]
Drug created on June 13, 2005 07:24 / Updated on July 19, 2018 17:49